Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — December 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #968

    Australia - From 1 January 2021, Darzalex® (daratumumab) will be listed for the first time in combination with bortezomib and dexamethasone, as a second-line treatment for patients with multiple myeloma https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/pbs-listings-bring-greater-hope-in-fight-against-multiple-myeloma-and-severe-psoriasis

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #969

      E L a bit surpriced that Janssen can file in Europe based on this study - but probably due to no approved therapy

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #970

        yes, and outcomes for these patients are very poor. Filing wasn't really such a surprise; they already flagged that they would. With FDA Breakthrough Therapy Designation in march, they submitted FDA BLA early this month , and recommendation on the request for accelerated assessment was on CHMP agenda this month

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #971

          will hopefully start producing revenue late 2021 🙂

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #972

            Yes and sales could go up rather quick when there is no approved drugs for these patients - probably not a big market but that also depends a bit on the price of the drug

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #973

              absolutely. Thyroid eye disease is not a big market either, and see how Tepezza is going... 😉

              1 Reply Last reply
              0
              • K Offline
                K Offline
                Klarussen
                wrote on sidst redigeret af
                #974

                Lav omsætning i aktien. Folk har nok travlt med at tanke op
                andre steder...

                1 Reply Last reply
                0
                • M Offline
                  M Offline
                  Mogan
                  wrote on sidst redigeret af
                  #975

                  Der er der ingen tvivl om, se bare på dagens C25. Mange aktier i meget fine stigninger.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #976

                    Remember that Priority Review Voucher Novartis had for Kesimpta, but that didn't really work very well...? Y-mAbs Announces Sale of Priority Review Voucher for $105mio... big business... https://www.marketscreener.com/quote/stock/Y-MABS-THERAPEUTICS-INC-46288936/news/Y-mAbs-Announces-Sale-of-Priority-Review-Voucher-32092094/

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #977

                      God morgen. 🙂

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #978

                        Tirsdagens danske avisuddrag med Egmont, Jysk og Brexit
                        https://www.proinvestor.com/investornyt/670700/tirsdagens-danske-avisuddrag-med-egmont-jysk-og-brexit

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          Plimsoller
                          wrote on sidst redigeret af
                          #979

                          God morgen 🙂

                          1 Reply Last reply
                          0
                          • K Offline
                            K Offline
                            Klarussen
                            wrote on sidst redigeret af
                            #980

                            Nå, ser da ud til at der er rift om Genmab-aktierne her på falderebet i 2020. Er det mon delvist p.gr. salget af voucheren?Tænker dollarkursen, retssagen med Janssen og hvor meget Horizons midlertidige produktionscut vil betyde for bundlinjen er nogle af de ikke-faglige spørgsmål som kan være med til at forme kursen i det kommende år. Skal vi i 3000 i 2021
                            ?

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              peter12
                              wrote on sidst redigeret af
                              #981

                              Hvad kan vi forvente med hexa-cd38 ? Den er planlagt til 2020 ? Voucheren var vist ikke Genmab ?

                              1 Reply Last reply
                              0
                              • K Offline
                                K Offline
                                Klarussen
                                wrote on sidst redigeret af
                                #982

                                Nå, det var Y-mabs der solgte voucheren, ikke Genmab ;-), så ingen ekstra indtægt der

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  GeorgeBest
                                  wrote on sidst redigeret af
                                  #983

                                  Hexa-CD38 IND submitted in October

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    GeorgeBest
                                    wrote on sidst redigeret af
                                    #984

                                    hexa-cd38 er vel 10 x mere potent end dara, så det der skal bevises er om den er safe...

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      GeorgeBest
                                      wrote on sidst redigeret af
                                      #985

                                      udover dette skal den prøves i diffuse large B-cell lymphoma, hvor dara fejlede https://ir.genmab.com/news-releases/news-release-details/genmab-signs-agreement-janssen-next-generation-cd38-antibody/

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        GeorgeBest
                                        wrote on sidst redigeret af
                                        #986

                                        BioNTech og CureVac har fået ordentlige tæsk den seneste uge. De var nok også i boble område forinden. Udover dette så bliver AstraZeneca/Oxford vaccinen formådentlig godkendt i UK og Indien i denne uge

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          GeorgeBest
                                          wrote on sidst redigeret af
                                          #987

                                          Den er væsentlig billigere end BioNTechs vaccine, og skal ikke nedfryses til -70 grader. Kan opbevares i en normal dybfryser. Gør livet noget lettere for sundhedssektoren

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger